Seadrill Ltd (NYSE:SDRL) is up 3.08% in pre-market trading to $6.70 after the oil giant reported second quarter earnings before market open that beat earnings estimates but fell short of revenue expectations. The company posted diluted earnings per share of $0.77, beating the analyst estimate of $0.59. However, the company did not reach revenue estimates of $1.173 billion, posting revenue for the quarter of $1.147 billion. Seadrill posted net operating income of $257 million, down from $361 million in the same quarter of last year. Shares of Seadrill have taken a beating this year as oil prices have fallen. In the past 12 months, shares of Seadrill have fallen approximately 80%. Shares are now hovering above its 52-week low of $6.15, down from its 52-week high of $37.46. According to the 3 analysts polled by TipRanks in the last 3 months, 2 are bearish on Seadrill and 1 is neutral. The average 12-month price target for SDRL is $10.00, marking a 54% potential upside from where shares last closed.
Amazon.com, Inc. (NASDAQ:AMZN) shares increased 1.93% in pre-market trading up to $510.43 after Raymond James analyst Aaron Kessler upgraded the company from Outperform to a Strong Buy with an unchanged price target of $640. Kessler sees the recent market pullback as an opportune entry point for the stock. He also notes that the third quarter is off to a “solid start,” and that “North America margins are at an inflection point driven by increasing scale efficiencies.” Amazon shares have been rising steadily in the past 12 months and are now trading at approximately $500, compared to its 52-week high of $580 and its 52-week low of $478. Three other analysts have either upgraded to bullish ratings or reiterated bullish ratings on Amazon in the past three days, citing it is a stock that should remain strong as uncertain economic times grip China. According to the 33 analysts polled by TipRanks in the last 3 months, 30 are bullish on Amazon and 3 are neutral. The average 12-month price target on the stock is $623.95, marking a 25% potential upside from where shares last closed.
Exelixis, Inc. (NASDAQ:EXEL) shares are up 9.57% to $6.18 after the biotechnology company announced that it has received approval for cobimetinib in Switzerland. Swissmedic, the licensing agency in Switzerland, approved the use of the melanoma drug to be used in combination with vemurafenib. The drug will be marketed as Cotellic in Switzerland and was developed in collaboration between Exelixis and Genentech. This is the first approval for the drug and the company hopes to receive more regulatory approvals in both the United States and European Union later this year. According to TipRanks, 2 analysts have rated Exelixis in the past 3 months. Of the 2 analysts, 1 is bullish and 1 is neutral. The average 12-month price target for the stock is $6, marking a 6% potential upside from where shares last closed.
SolarCity Corp (NASDAQ:SCTY) jumped 5.10% up to $2.20 in pre-market trading after Morgan Stanley analyst Stephen Byrd upgraded the company from Equal weight to Overweight with a $93 price target. The analyst acknowledges that the stock is down 21% in the past month, but adds that this is “inconsistent” with the company’s strong fundamentals. This rating comes three days after founder Elon Musk bought approximately $5 million worth of shares of the company. This transaction increased his holdings in his company by 0.6%, now owning about 21 million shares. According to the 10 analysts polled by TipRanks in the last 3 months, 8 are bullish on SolarCity and 2 are neutral. The average 12-month price target for the stock is $76.89, marking a 79% potential upside from where shares last closed.